The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Open accessAbstract
OBJECTIVE: To determine the risk of an adverse upper gastrointestinal event in patients taking different cyclo-oxygenase-2 inhibitors compared with non-selective non-steroidal anti-inflammatory drugs. DESIGN: Nested case-control study. SETTING: 367 general practices contributing to the UK QRESEARCH database, spread throughout every strategic health authority and each health board in England, Wales, and Scotland. PARTICIPANTS: Patients aged 25 or more with a first ever diagnosis of an adverse upper gastrointestinal event (peptic ulcer or haematemesis) between 1 August 2000 and 31 July 2004 and up to 10 controls per case matched for age, sex, calendar time, and practice. MAIN OUTCOME MEASURES: Unadjusted and adjusted odds ratios for adverse upper gastrointestinal events associated with celecoxib, rofecoxib, ibuprofen, diclofenac, naproxen, other selective and non-selective non-steroidal anti-inflammatory drugs, and aspirin. RESULTS: The incidence of adverse upper gastrointestinal events was 1.36 per 1000 person years (95% confidence interval 1.34 to 1.39). We identified 9407 incident cases and 88 867 matched controls. Increased risks of adverse gastrointestinal events were associated with current use of cyclo-oxygenase-2 inhibitors and with conventional non-steroidal anti-inflammatory drugs. Risks were reduced after adjustment for confounders but remained significantly increased for naproxen (adjusted odds ratio 2.12, 95% confidence interval 1.73 to 2.58), diclofenac (1.96, 1.78 to 2.15), and rofecoxib (1.56, 1.30 to 1.87) but not for current use of celecoxib (1.11, 0.87 to 1.41). We found clinically important interactions with current use of ulcer healing drugs that removed the increased risks for adverse gastrointestinal events for all groups of non-steroidal anti-inflammatory drugs except diclofenac, which still had an increased odds ratio (1.49, 1.26 to 1.76). CONCLUSION: No consistent evidence was found of enhanced safety against gastrointestinal events with any of the new cyclo-oxygenase-2 inhibitors compared with non-selective non-steroidal anti-inflammatory drugs. The use of ulcer healing drugs reduced the increased risk of adverse gastrointestinal outcomes with all groups of non-steroidal anti-inflammatory drugs, but for diclofenac the increased risk remained significant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The electronic patient record in primary care–regression or progression? A cross sectional study.
Hippisley-Cox, J., Pringle, M., Cater, R., Wynn, A., Hammersley, V., Coupland, C., Hapgood, R., Horsfield, P., Teasdale, S., & Johnson, C. (2003) · BMJ · doi:10.1136/bmj.326.7404.1439 · Cited by 176
Self-citation
Cited by
Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?
Wallace, J. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00004.2008 · Cited by 716
Ibuprofen: pharmacology, efficacy and safety
Rainsford, K. D. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-0016-x · Cited by 667
Hurley, M. V., Walsh, N. E., Mitchell, H., Nicholas, J., & Patel, A. (2012) · Arthritis Care & Research · doi:10.1002/acr.20642 · Cited by 407
Estimates of benefits and harms of prophylactic use of aspirin in the general population
Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu225 · Cited by 382
Castellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., Sturkenboom, M., Perez-Gutthann, S., & Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project (2012) · Drug Safety · doi:10.1007/bf03261999 · Cited by 341
Metadata
- Authors
- Hippisley-Cox, J., Coupland, C., & Logan, R.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2005-12-01
- Volume
- 331
- Issue
- 7528
- Pages
- 1310-1316
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2010860405
- Cited by
- 243
- References
- 1
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. https://app.cochat.ai/papers/10.1136/bmj.331.7528.1310
- The paper
- Hippisley-Cox, J., Coupland, C., & Logan, R. (2005). Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. https://doi.org/10.1136/bmj.331.7528.1310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.